Merck & Co./$MRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Ticker
- $MRK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 74,000
- Headquarters
- Rahway, United States
- Website
- www.merck.com
Merck & Co. Metrics
BasicAdvanced
$363B
115.68
$1.27
0.21
$3.40
2.31%
Price and volume
Market cap
$363B
Beta
0.21
52-week high
$156.92
52-week low
$82.01
Average daily volume
10M
Dividend rate
$3.40
Financial strength
Current ratio
1.323
Quick ratio
0.742
Long term debt to equity
1.217
Total debt to equity
1.284
Dividend payout ratio (TTM)
261.52%
Interest coverage (TTM)
13.47%
Profitability
EBITDA (TTM)
15,178
Gross margin (TTM)
75.90%
Net profit margin (TTM)
4.77%
Operating margin (TTM)
14.80%
Effective tax rate (TTM)
46.72%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
11.87%
Return on equity (TTM)
6.96%
Valuation
Price to earnings (TTM)
115.678
Price to revenue (TTM)
5.478
Price to book
7.93
Price to tangible book (TTM)
-251.13
Price to free cash flow (TTM)
22.728
Free cash flow yield (TTM)
4.40%
Free cash flow per share (TTM)
6.478
Dividend yield (TTM)
2.31%
Forward dividend yield
2.31%
Growth
Revenue change (TTM)
4.64%
Earnings per share change (TTM)
-80.37%
3-year revenue growth (CAGR)
4.51%
10-year revenue growth (CAGR)
5.37%
3-year earnings per share growth (CAGR)
1.25%
10-year earnings per share growth (CAGR)
-3.53%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
6.20%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Analyst projections of the future price of Merck & Co. stock.
Bulls say / Bears say
Second-quarter worldwide sales rose 5% to $16.6 billion, and Merck raised its full-year sales forecast to $66.3–$67.3 billion. This points to solid near-term trading despite pressure from older products. (Merck.com)
Newer products are growing quickly: Winrevair sales rose 75% to $588 million in the second quarter, while the injectable Keytruda Qlex generated $463 million. Their growth could broaden the business beyond established medicines. (Merck.com)
Keytruda still accounts for close to half of Merck’s sales, leaving the company exposed to its expected US patent expiry in 2028. Management also expects its growth to moderate as it approaches peak use in several indications. (Labiotech.eu, The Motley Fool)
A Dutch court ordered Merck to stop selling the injectable Keytruda Qlex in several European countries after finding it infringed a rival’s patent. This threatens one of Merck’s strategies for defending its largest franchise ahead of patent expiry. (Bloomberg Law)
Merck and Daiichi withdrew their US filing for a lung-cancer drug after the FDA said the supporting data were insufficient for accelerated approval. The setback delays a potential pipeline contributor as Merck prepares for Keytruda’s eventual loss of exclusivity. (Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Merck & Co. News
AllArticlesVideos
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Investopedia11 hours ago
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Business Wire13 hours ago
Why Is Moderna Stock Sinking Thursday?
Benzinga13 hours ago
Funds containing Merck & Co.
AllUSDEURGBP
Fund name | Fund size | $MRK weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector$XLVS | $552M | 6.10% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 6.10% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 5.70% |
SPDR MSCI World Health Care$WHEA | $708M | 4.21% |
SPDR MSCI World Health Care£HEAW | $708M | 4.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.